COMPARISON OF SURVIVAL AMONG PATIENTS WITH BREAST CANCER TREATED AT FIRST TEACHING HOSPITAL，CHANGCHU

ＣＯＭＰＡＲＩＳＯＮＯＦＳＵＲＶＩＶＡＬＡＭＯＮＧＰＡＴＩＥＮＴＳＷＩＴＨＢＲＥＡＳＴＣＡＮＣＥＲＴＲＥＡＴＥＤＡＴＦＩＲＳＴＴＥＡＣＨＩＮＧＨＯＳＰＩＴＡＬ，ＣＨＡＮＧＣＨＵＮ，ＣＨＩＮＡ，ＡＮＤＳＡＩＮＴＳＡＣＲＥＭＥＮＴＨＯＳＰＩＴＡＬ，ＱＵ■...     

DIAGNOSIS AND SURGICAL TREATMENT OF 103 PATIENTS WITH EARLY ESOPHAGEAL CANCER AND CARDIAC CANCER OF STOMACH

ＤＩＡＧＮＯＳＩＳＡＮＤＳＵＲＧＩＣＡＬＴＲＥＡＴＭＥＮＴＯＦ１０３ＰＡＴＩＥＮＴＳＷＩＴＨＥＡＲＬＹＥＳＯＰＨＡＧＥＡＬＣＡＮＣＥＲＡＮＤＣＡＲＤＩＡＣＣＡＮＣＥＲＯＦＳＴＯＭＡＣＨＷｕＣｈａｎｇｒｏｎｇ；ＺｈａｎｇＺｈｅｎｂｉｎ；ＺｈｕＺｏｎｇｈ...     

SIMULTANEOUS THORACO－CRANIAL OPERATION FOR THE TREATMENT OF LUNG CANCER WITH BRAIN METASTASES

ＳＩＭＵＬＴＡＮＥＯＵＳＴＨＯＲＡＣＯ－ＣＲＡＮＩＡＬＯＰＥＲＡＴＩＯＮＦＯＲＴＨＥＴＲＥＡＴＭＥＮＴＯＦＬＵＮＧＣＡＮＣＥＲＷＩＴＨＢＲＡＩＮＭＥＴＡＳＴＡＳＥＳＣｈｅｎＪｉａｎ陈建；ＬｉｕＤａｏｋｕｎ刘道坤；ＬｉｕＪｕｎｈｕａ刘俊华；ＳｈｉＺｈｏ...     

CLINICOPATHOLOGIC FEATURES AND HEPATECTOMY IN THE ELDERLY PATIENTS WITH PRIMARY LIVER CANCER

ＣＬＩＮＩＣＯＰＡＴＨＯＬＯＧＩＣＦＥＡＴＵＲＥＳＡＮＤＨＥＰＡＴＥＣＴＯＭＹＩＮＴＨＥＥＬＤＥＲＬＹＰＡＴＩＥＮＴＳＷＩＴＨＰＲＩＭＡＲＹＬＩＶＥＲＣＡＮＣＥＲＺｈｏｕＸｉｎｄａ周信达ＴａｎｇＺｈａｏｙｏｕ汤钊猷ＹｕＹｅｑｉｎ余业勤ＭａＺｅｎｇｃｈ...     

DETECTION OF OCCULT TUMOR CELLS IN RESECTED LYMPH NODES OF PATIENTS WITH STAGE I CARCINOMA AND ITS CLINICOPATHOLOGICAL SIGNIFICANCE

ＤＥＴＥＣＴＩＯＮＯＦＯＣＣＵＬＴＴＵＭＯＲＣＥＬＬＳＩＮＲＥＳＥＣＴＥＤＬＹＭＰＨＮＯＤＥＳＯＦＰＡＴＩＥＮＴＳＷＩＴＨＳＴＡＧＥＩＣＡＲＣＩＮＯＭＡＡＮＤＩＴＳＣＬＩＮＩＣＯＰＡＴＨＯＬＯＧＩＣＡＬＳＩＧＮＩＦＩＣＡＮＣＥＣｈｅｎＺｈａｏｌｕｎ...     

THE FINDING OF PATIENTS SUFFERING FROM NASOPHARYNGEAL CARCINOMA （NPC） WHO CONTACTED WITH THE HEXAMETHYLPHOSPHORAMIDE （HMPA） F

黄迪，张锦明，梁小曼ＴＨＥＦＩＮＤＩＮＧＯＦＰＡＴＩＥＮＴＳＳＵＦＦＥＲＩＮＧＦＲＯＭＮＡＳＯＰＨＡＲＹＮＧＥＡＬＣＡＲＣＩＮＯＭＡ（ＮＰＣ）ＷＨＯＣＯＮＴＡＣＴＥＤＷＩＴＨＴＨＥＨＥＸＡＭＥＴＨＹＬＰＨＯＳＰＨＯＲＡＭＩＤＥ（ＨＭＰＡ）ＦＯＲＡＬＯ...     

THERAPEUTIC EFFECTS OF rhTNF ALONE AND INCOMBINATION WITH KENGSHENGMYCIN INEXPERIMENTAL HUMAN OVARIAN CANCER

ＴＨＥＲＡＰＥＵＴＩＣＥＦＦＥＣＴＳＯＦｒｈＴＮＦＡＬＯＮＥＡＮＤＩＮＣＯＭＢＩＮＡＴＩＯＮＷＩＴＨ　ＫＥＮＧＳＨＥＮＧＭＹＣＩＮＩＮＥＸＰＥＲＩＭＥＮＴＡＬＨＵＭＡＮＯＶＡＲＩＡＮＣＡＮＣＥＲＺｈａｏＥｎｆｅｎｇ赵恩锋；ＺｈｏｕＭｅｉｑｉｎｇ周美清...     

CONGENITAL EXPRESSION OF mdr-1 GENE IN FRESH CANCER TISSUES FROM SEVERAL HIGH-INCIDENCE NEOPLASMS WITHOUT PREOPERATIVE CHEMOTHERAPY

ＣＯＮＧＥＮＩＴＡＬＥＸＰＲＥＳＳＩＯＮＯＦｍｄｒ１ＧＥＮＥＩＮＦＲＥＳＨＣＡＮＣＥＲＴＩＳＳＵＥＳＦＲＯＭＳＥＶＥＲＡＬＨＩＧＨＩＮＣＩＤＥＮＣＥＮＥＯＰＬＡＳＭＳＷＩＴＨＯＵＴＰＲＥＯＰＥＲＡＴＩＶＥＣＨＥＭＯＴＨＥＲＡＰＹＺｈａｎｇＹａｎｍ...     

THE IN VITRO POTENTIATION OF LAK CELL CYTOTOXICITY IN CANCER AND AIDS PATIENTS INDUCED BY F3—A FRACTIONATED EXTRACT OF ASTRAG

ＴＨＥＩＮＶＩＴＲＯＰＯＴＥＮＴＩＡＴＩＯＮＯＦＬＡＫＣＥＬＬＣＹＴＯＴＯＸＩＣＩＴＹＩＮＣＡＮＣＥＲＡＮＤＡＩＤＳＰＡＴＩＥＮＴＳＩＮＤＵＣＥＤＢＹＦ３—ＡＦＲＡＣＴＩＯＮＡＴＥＤＥＸＴＲＡＣＴＯＦＡＳＴＲＡＧＡＬＵＳＭＥＭＢＲＡＮＡＣＥＵＳＣｈｕ...     

ENHANCEMENT OF MORPHOLOGICAL AND ONCOGENIC TRANSFORMATION OF MOUSE CELLS WITH 12－O－TETRA－DECANOYL PHORBOL－13－ACETATE FOLLOWIN

ＥＮＨＡＮＣＥＭＥＮＴＯＦＭＯＲＰＨＯＬＯＧＩＣＡＬＡＮＤＯＮＣＯＧＥＮＩＣＴＲＡＮＳＦＯＲＭＡＴＩＯＮＯＦＭＯＵＳＥＣＥＬＬＳＷＩＴＨ１２－Ｏ－ＴＥＴＲＡＤＥＣＡＮＯＹＬＰＨＯＲＢＯＬ－１３－ＡＣＥＴＡＴＥＦＯＬＬＯＷＩＮＧＨＥＲＰＥＳＳＩＮＰＬＥ...     

胃癌患者术中腹腔热灌注化疗的临床研究

目的：探讨胃癌根治术中一次性腹腔温热灌注化疗的临床疗效。方法：将术中行一次性腹腔温热灌注化疗的50例胃癌患者（治疗组）与未行此方法治疗的100例患者（对照组）的腹腔游离癌细胞检出率及预后等情况进行对比。结果：治疗组的温热灌注液游离癌细胞检出率为7．4％；对照组冲洗液的癌细胞检出率为30．8％。治疗组与对照组术后两年内腹腔复发率分别为14．6％和38．7％（P〈0．01）。治疗组术后1、2、3年生存率分别为100％、79％和60％；对照组则为95．1％、50．2％和35．2％，两组2、3年生存率比较，差异有显著性（P〈0．01）。结论：一次性腹腔温热灌注化疗简便、高效、安全，具有杀灭腹腔游离癌细胞的作用，可降低患者术后腹腔复发率和提高生存率。     

温热重蒸馏水对人胃癌细胞系杀伤效应与在胃癌根治切除术中腹腔灌洗疗效的分析

Objective:To evaluate the effect andindications of radical gastrectomy combined with peritoneal lavage with thermal double distilled water(DDW)or DDW plus chlorthexidine acetate.Methods:On the bases of the study on the killing effect of 43℃ DDW on human gastric cancer cell line MGC-803 and its inhibiting effect on ascitic tumor of SY86B morse,500 cases of gastric cancer who underwent radical gastectomy from January 1986 to December 1995 were divided into three groups:group A(n=198) subject to radical gastrectomy and peritoneal lavage for 10min with 4000ml DDW at 43℃ ;group B(n=89)subject to radical gastrectomy and peritoneal lavage for 4min with 4000ml DDW plus 0.6g chlorthexidine acetate,and grup C(n=213) subject to radical gastrectomy and peritoneal lavage for 4 min with 4000ml normal saline at room temperature as control.Results Human gastric cancer cells MGC-803 could be completely killed by treatment of either 43℃ DDW for 10min or DDW plus 0.015ml/L chlorhexidine acetate for 4 min.Clinical trials proved group A and group B(called lavage group as a whole)had almost the same curative effects.The 1-year survival rate and 3-year survival rate were similar in different stages among the groups.The 5-year survival rate was 63.8% in the lavage group and 51.2% in the control group respectively.Most of the cases with good effect were at the mid-stage (Ⅱand Ⅲ stage).Conclusion Radical gastrectom combined with peritoneal peritoneal lavage before closing the abdomen has satisfying effect on patients with gastric cancer at stage Ⅱ and stage ⅢA.     

Observations on staging of advanced gastric cancer using contact rigid endoscopy

A rigid contact scope is a recent development of optical instrument which allows observations of the superficial layers of the mucosai epithelium in gynecology and otorhinolaryngology. To assess the evaluation of 25 patients with advanced gastric cancer, whose lesions had been diagnosed to be more than T3 or suspected to have peritoneal deeding, we performed pre operative laparoscope with rigid contact scope. After inspecting a usual laparoscopic observation of the abdominal cavity, serosal exporsure and peritoneal seeding were confirmed. All the patients who had serosal exporsure and cancer cells showed an irregularity of cell distribution with the extent of heterogeneity of the cells with nuclei size and shape. Five patients had peritoneal seeding, and the findings with rigid contact scope showed a similar view to cancer cells which were observed in serosal exposure. The result suggests that this new endoscopic technique enabled a new diagnostic approach in advanced gastric cancer.     

我国进展期胃癌围手术期行预防性腹腔热灌注化疗的研究进展

胃癌是我国最常见的恶性肿瘤之一, 术后5年生存率仅为10%~49%, 术后腹膜复发是影响其生存率的主要原因。腹腔热灌注化疗经过20多年的研究和发展, 已得到了充分的认识和较好的临床应用效果。预防性应用腹腔热灌注化疗有助于减少术后复发率, 提高胃癌的5年生存率, 改善生存质量, 提升胃癌的总体疗效。本文对近年来我国对进展期胃癌AGC行预防性腹腔热灌注化疗(hyperthermic intraperitonral chemotherapy, HIPEC)的临床开展情况作一综述。      

Intraperitoneal free cancer cells and their viability in gastric cancer.

Free cancer cells in the peritoneal cavity of 100 patients with gastric cancer were examined by means of Douglas lavage, and their viability was estimated by 3H-thymidine uptake with autoradiographical technic. Furthermore, the effect of mitomycin-C on the viability of free cancer cells in the peritoneal cavity was studied. The appearance of intraperitoneal free cancer cells was dependent on the degree of invasion of cancer to the gastric serosa; that is, free cancer cells were not found in cases without serosal invasion, but were found in 48% with serosal invasion. The viability of free cancer cells in the peritoneal cavity was relatively high, but could be suppressed remarkably by intraperitoneal administration of 10 mg of mitomycin-C.     

腹腔镜胃癌根治术无瘤技术的应用研究

目的:探讨应用无瘤技术后腹腔镜下胃癌根治术对肿瘤脱落细胞的影响,评价其安全性及可行性。方法:收集65例行腹腔镜胃癌手术患者切除前后腹腔冲洗液,细胞学检测腹腔游离癌细胞,并以流式细胞学(FCM)方法检测腹腔冲洗液癌胚抗原(CEA)及基质金属蛋白酶-7（MMP-7),对比术前、术后检出率。结果:65例规范无瘤操作的腹腔镜胃癌根治术患者腹腔游离癌细胞术前、术后检出率分别为6.15%（4/65）和9.23%（6/65）,CEA检测阳性率术前、术后分别为46.2%（30/65）和52.3%（34/65）,MMP-7检测阳性率术前、术后分别为56.9%（37/65）和 64.6%(42/65),术后较手术前高,但两者差异无统计学意义（P>0.05）。结论:严格遵守无瘤操作规程的腹腔镜胃癌根治术,不增加癌细胞的脱落,也不增加腹腔种植转移几率,是安全可行的。     

The third report from Sapporo Tsukisamu Hospital--chemotherapy for patients with advanced gastric cancer (peritoneal dissemination, peritonitis carcinomatosa)

Recently, it became possible to reduce the size of tumors in patients with advanced or relapsed gastric cancer by chemotherapy with the combination of several kinds of anti-cancer drugs which are all effective and allowed for use with gastric cancer patients. However, chemotherapy alone can not cure patients with advanced gastric cancer that was shown to improve median survival time (MST), compared with patients provided with the best supportive care (BSC). According to reports from Europe, US and Japan,the MST of patients with advanced gastric cancer and those with peritoneal expansion treated by chemotherapy is almost 7-12 months and 5-6 months,respectively, both of which are short and unsatisfactory. From March 2002, we started to treat patients with advanced gastric cancer (stage IV) with a new regimen; intermittent dosage of 5-FU (-->S-1), CDDP and paclitaxel utilizing the difference of cell cycle between normal and cancer cells (intermittent FP . weekly PTX). In the present study, therefore, we analyzed advanced gastric cancer patients with peritoneal expansion (9 cases, 4 with cancerous peritonitis) treated with this regimen. The results were as follows. The one-and 2-year survival rate was 55.6% and 27.8%, respectively, and the MST was 14 months. Four patients (44.4%) had hematological toxicities over grade 3. All of them had anemia (3 cases) and neutropenia (3 cases). Toxicities of thrombocytopenia were all under grade 1 and nonhematological toxicities were all under grade 2, which were clinically manageable. These results, although the sample was small, suggested that this may contribute to the extension of survival time of patients with stage IV advanced gastric cancer with peritoneal expansion.